
15/07/2025
A milestone worth celebrating!
The RBM Partnership to End Malaria applauds the landmark approval of the first malaria medicine specifically for newborns and young infants (from 2kg to under 5kg).
For too long, healthcare workers faced an impossible choice: crush malaria tablets for infants, risking fatal under/over-dosing - the smallest and most vulnerable lacked a proven treatment. NO MORE.
With rapid approvals expected in 8 African countries and Novartis' commitment to not-for-profit access, we’re one step closer to a malaria-free future.
This isn’t just a breakthrough—it’s a tool for justice.
Reduces catastrophic health spending for poor families
Empowers mothers (primary caregivers) with reliable treatment
Closes the health gap for the most vulnerable
Malaria thrives on inequality. By ensuring infants get the right dose, we protect development, strengthen health systems, and fuel economic growth.
Every child deserves a fair start. Let’s get this life-saving tool to every clinic!
Together, we .